OKUR
OnKure Therapeutics, Inc.$3.25-0.10 (-2.84%)Prev Close$3.34·MCap$46.1M·P/E—·Vol84.1K·Yield—
▲
Buys (12M)
0
$0.00
▼
Sells (12M)
8
$4.7K
◆
Net Activity
Net Seller
$4.7K
●
Active Insiders
2
last 12 mo
Over the past 12 months, insider activity at OnKure Therapeutics, Inc. (OKUR) has been exclusively selling, with 0 insider purchases totaling $0.00 and 8 insider sales totaling $4.7K. The most recent insider transaction was by Saccomano Nicholas A (director, officer: President and CEO), who sold $357.46 worth of shares on Mar 24, 2026. OnKure Therapeutics, Inc. operates in the Healthcare sector, within the Biotechnology industry, with a market cap of $46.1M.
OKUR Insider Trading Activity
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | Saccomano Nicholas A | director, officer: President and CEO | Sell | 86 | $4.16 | $357.46 | 7,333 |
| Mar 24, 2026 | Leverone Jason A. | officer: Chief Financial Officer | Sell | 301 | $4.16 | $1.3K | 16,000 |
| Dec 22, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 302 | $2.97 | $896.25 | 0 |
| Dec 22, 2025 | Saccomano Nicholas A | President and CEO | Sell | 87 | $2.97 | $258.19 | 0 |
| Sep 22, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $2.62 | $794.92 | 0 |
| Sep 22, 2025 | Saccomano Nicholas A | President and CEO | Sell | 88 | $2.62 | $230.87 | 0 |
| Jun 23, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $2.38 | $722.41 | 0 |
| Jun 23, 2025 | Saccomano Nicholas A | President and CEO | Sell | 88 | $2.38 | $209.81 | 0 |
| Apr 4, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 3,122 | $2.94 | $9.2K | 0 |
| Apr 4, 2025 | Saccomano Nicholas A | President and CEO | Sell | 874 | $2.94 | $2.6K | 0 |
| Sep 26, 2024 | Leonard Braden Michael | Buy | 98,346 | $1.47 | $144.7K0.7% OS | 3,457,395 | |
| Sep 19, 2024 | Leonard Braden Michael | Buy | 56,106 | $1.36 | $76.2K | 3,359,049 | |
| Sep 16, 2024 | Leonard Braden Michael | Buy | 358,923 | $1.35 | $484.3K2.6% OS | 3,302,943 | |
| Aug 14, 2024 | Leonard Braden Michael | Buy | 271,826 | $1.40 | $380.6K2.0% OS | 2,944,020 | |
| May 16, 2024 | Leonard Braden Michael | Buy | 414,281 | $1.54 | $639.6K3.0% OS | 2,672,194 | |
| Aug 29, 2023 | Hall Ashley | Chief Development Officer | Sell | 15,625 | $6.28 | $98.1K | 39,600-28% |
| Jun 23, 2023 | Novo Holdings A/S | 10% Owner | Sell | 100,000 | $7.10 | $709.7K0.7% OS | 3,330,337 |
| May 10, 2023 | O'Donnell Niall | Director | Buy | 125,000 | $8.00 | $1.00M0.9% OS | 2,188,713 |
| Sep 2, 2022 | Cruse Michael | Chief Operating Officer | Buy | 7,500 | $3.39 | $25.4K | 13,697+121% |
| Aug 31, 2022 | Cruse Michael | Chief Operating Officer | Buy | 7,255 | $3.20 | $23.2K | 31,758+30% |
| Aug 26, 2021 | Cruse Michael | Senior VP-Corporate Operations | Buy | 2,500 | $7.45 | $18.6K | 2,500 |
| Aug 26, 2021 | FLESHER GREGORY J. | President and CEO | Buy | 8,000 | $8.00 | $64.0K | 8,000 |
| Aug 26, 2021 | Jindal Vineet R. | Chief Financial Officer | Buy | 5,000 | $7.44 | $37.2K | 5,000 |
| Jul 15, 2021 | Johnson Wendy S. | Chief Development Officer | Sell | 111,736 | $8.50 | $949.8K0.8% OS | 0Exit |
| Jul 15, 2021 | Muralidhar Bali | Director | Buy | 111,736 | $8.50 | $949.8K0.8% OS | 2,073,957 |
| Jun 25, 2021 | Muralidhar Bali | Director | Buy | 20,710 | $9.28 | $192.2K | 1,962,221 |
| Jun 23, 2021 | Muralidhar Bali | Director | Buy | 47,274 | $8.94 | $422.4K | 1,941,511 |
| Jun 10, 2021 | Muralidhar Bali | Director | Buy | 16,605 | $9.50 | $157.7K | 1,894,237 |
| Jun 7, 2021 | Muralidhar Bali | Director | Buy | 12,357 | $9.26 | $114.4K | 1,877,632 |
| Jun 2, 2021 | Muralidhar Bali | Director | Buy | 14 | $9.50 | $133.00 | 1,865,275 |
| May 28, 2021 | Muralidhar Bali | Director | Buy | 7,035 | $9.36 | $65.9K | 1,865,261 |
| Apr 15, 2021 | Muralidhar Bali | Director | Buy | 200,000 | $15.00 | $3.00M1.5% OS | 1,858,226 |
| Apr 15, 2021 | New Enterprise Associates 15, L.P. | 10% Owner | Buy | 666,666 | $15.00 | $10.00M4.9% OS | 4,785,494 |
| Apr 15, 2021 | O'Donnell Niall | Director | Buy | 200,000 | $15.00 | $3.00M1.5% OS | 2,063,713 |
| Apr 14, 2021 | Novo Holdings A/S | 10% Owner | Buy | 666,666 | $15.00 | $10.00M4.9% OS | 3,430,377 |
| Apr 13, 2021 | RiverVest Venture Fund III, L.P. | 10% Owner | Buy | 200,000 | $15.00 | $3.00M1.5% OS | 2,409,220 |
OKUR Insider Buying Activity
The following table shows recent insider purchases of OnKure Therapeutics, Inc. (OKUR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Sep 26, 2024 | Leonard Braden Michael | Buy | 98,346 | $1.47 | $144.7K0.7% OS | 3,457,395 | |
| Sep 19, 2024 | Leonard Braden Michael | Buy | 56,106 | $1.36 | $76.2K | 3,359,049 | |
| Sep 16, 2024 | Leonard Braden Michael | Buy | 358,923 | $1.35 | $484.3K2.6% OS | 3,302,943 | |
| Aug 14, 2024 | Leonard Braden Michael | Buy | 271,826 | $1.40 | $380.6K2.0% OS | 2,944,020 | |
| May 16, 2024 | Leonard Braden Michael | Buy | 414,281 | $1.54 | $639.6K3.0% OS | 2,672,194 | |
| May 10, 2023 | O'Donnell Niall | Director | Buy | 125,000 | $8.00 | $1.00M0.9% OS | 2,188,713 |
| Sep 2, 2022 | Cruse Michael | Chief Operating Officer | Buy | 7,500 | $3.39 | $25.4K | 13,697+121% |
| Aug 31, 2022 | Cruse Michael | Chief Operating Officer | Buy | 7,255 | $3.20 | $23.2K | 31,758+30% |
| Aug 26, 2021 | Cruse Michael | Senior VP-Corporate Operations | Buy | 2,500 | $7.45 | $18.6K | 2,500 |
| Aug 26, 2021 | FLESHER GREGORY J. | President and CEO | Buy | 8,000 | $8.00 | $64.0K | 8,000 |
| Aug 26, 2021 | Jindal Vineet R. | Chief Financial Officer | Buy | 5,000 | $7.44 | $37.2K | 5,000 |
| Jul 15, 2021 | Muralidhar Bali | Director | Buy | 111,736 | $8.50 | $949.8K0.8% OS | 2,073,957 |
| Jun 25, 2021 | Muralidhar Bali | Director | Buy | 20,710 | $9.28 | $192.2K | 1,962,221 |
| Jun 23, 2021 | Muralidhar Bali | Director | Buy | 47,274 | $8.94 | $422.4K | 1,941,511 |
| Jun 10, 2021 | Muralidhar Bali | Director | Buy | 16,605 | $9.50 | $157.7K | 1,894,237 |
| Jun 7, 2021 | Muralidhar Bali | Director | Buy | 12,357 | $9.26 | $114.4K | 1,877,632 |
| Jun 2, 2021 | Muralidhar Bali | Director | Buy | 14 | $9.50 | $133.00 | 1,865,275 |
| May 28, 2021 | Muralidhar Bali | Director | Buy | 7,035 | $9.36 | $65.9K | 1,865,261 |
| Apr 15, 2021 | Muralidhar Bali | Director | Buy | 200,000 | $15.00 | $3.00M1.5% OS | 1,858,226 |
| Apr 15, 2021 | New Enterprise Associates 15, L.P. | 10% Owner | Buy | 666,666 | $15.00 | $10.00M4.9% OS | 4,785,494 |
| Apr 15, 2021 | O'Donnell Niall | Director | Buy | 200,000 | $15.00 | $3.00M1.5% OS | 2,063,713 |
| Apr 14, 2021 | Novo Holdings A/S | 10% Owner | Buy | 666,666 | $15.00 | $10.00M4.9% OS | 3,430,377 |
| Apr 13, 2021 | RiverVest Venture Fund III, L.P. | 10% Owner | Buy | 200,000 | $15.00 | $3.00M1.5% OS | 2,409,220 |
OKUR Insider Selling Activity
The following table shows recent insider sales of OnKure Therapeutics, Inc. (OKUR) stock reported via SEC Form 4 filings.
| Date | Insider | Role | Type | Shares | Avg Price | Value | Shares After |
|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | Saccomano Nicholas A | director, officer: President and CEO | Sell | 86 | $4.16 | $357.46 | 7,333 |
| Mar 24, 2026 | Leverone Jason A. | officer: Chief Financial Officer | Sell | 301 | $4.16 | $1.3K | 16,000 |
| Dec 22, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 302 | $2.97 | $896.25 | 0 |
| Dec 22, 2025 | Saccomano Nicholas A | President and CEO | Sell | 87 | $2.97 | $258.19 | 0 |
| Sep 22, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $2.62 | $794.92 | 0 |
| Sep 22, 2025 | Saccomano Nicholas A | President and CEO | Sell | 88 | $2.62 | $230.87 | 0 |
| Jun 23, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 303 | $2.38 | $722.41 | 0 |
| Jun 23, 2025 | Saccomano Nicholas A | President and CEO | Sell | 88 | $2.38 | $209.81 | 0 |
| Apr 4, 2025 | Leverone Jason A. | Chief Financial Officer | Sell | 3,122 | $2.94 | $9.2K | 0 |
| Apr 4, 2025 | Saccomano Nicholas A | President and CEO | Sell | 874 | $2.94 | $2.6K | 0 |
| Aug 29, 2023 | Hall Ashley | Chief Development Officer | Sell | 15,625 | $6.28 | $98.1K | 39,600-28% |
| Jun 23, 2023 | Novo Holdings A/S | 10% Owner | Sell | 100,000 | $7.10 | $709.7K0.7% OS | 3,330,337 |
| Jul 15, 2021 | Johnson Wendy S. | Chief Development Officer | Sell | 111,736 | $8.50 | $949.8K0.8% OS | 0Exit |
OKUR Insiders
Similar Stocks to OKUR
VRTX
Vertex Pharmaceuticals Incorporated
$436.80-3.02%
$114.32B
REGN
Regeneron Pharmaceuticals, Inc.
$699.83-1.87%
$73.44B
ALNY
Alnylam Pharmaceuticals, Inc.
$289.07-1.46%
$39.18B
RVMD
Revolution Medicines, Inc.
$145.16-2.80%
$31.78B
INSM
Insmed Incorporated
$109.78-5.14%
$25.06B
UTHR
United Therapeutics Corporation
$568.58-1.47%
$24.13B
ROIV
Roivant Sciences Ltd.
$29.29-0.08%
$20.96B
MRNA
Moderna, Inc.
$49.04-2.34%
$19.46B